Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis

Pharmacotherapy

Volumn 25, Issue 6, 2005, Pages 839-846

  Lewis II, James S ^a,c   Boucher, Helen W ^d   Lubowski, Teresa J ^e   Ambegaonkar, Ambarish J ^e   Day, David L ^e   Patterson, Thomas F ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center at San Antonio   (United States)

^c UNIVERSITY HEALTH SYSTEM   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e PFIZER INC   (United States)

Author keywords

AmBd; Amphotericin B deoxycholate; Invasive aspergillosis; Pharmacoeconomics; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; COMPUTER PROGRAM; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; FOLLOW UP; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; UNIVERSITY HOSPITAL;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; ECONOMICS, PHARMACEUTICAL; HUMANS; INJECTIONS, INTRAVENOUS; MULTICENTER STUDIES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; TRIAZOLES;

EID: 19444363838     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.6.839     Document Type: Article

References (14)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998;26(4):781-803.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32(3):358-66.
3. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. 13 aspergillus study group. Medicine (Baltimore) 2000;79(4):250-60.
4. Wilson LS, Reyes CM, Stolpman M, et al. The direct cost and incidence of systemic fungal infections. Value Health 2002;5(1):26-34.
5. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizaiions in the United States. Clin Infect Dis 2000;31(6):1524-8.
6. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003;37(suppl 3):S157-87.
7. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15.
8. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3(4):419-58.
9. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696-709.
10. Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45(12):3487-96.
11. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-18.
12. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis 2001;32(5):686-93.
13. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346(4):225-34.
14. Lewis JS, Hill GL, Laurel YM, et al. Financial impact of voriconazole (VCZ) use in a university teaching hospital [abstr 163]. In: Program and abstracts of the 41st annual meeting of the Infectious Diseases Society of America. Washington, DC: Infectious Diseases Society of America, 2003.